Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

226 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cunningham D, et al. N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Clinical Trial.
The medical treatment of colorectal cancer: actual status and new developments.
Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. Van Cutsem E, et al. Hepatogastroenterology. 1999 Mar-Apr;46(26):709-16. Hepatogastroenterology. 1999. PMID: 10370599 Review.
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Van Cutsem E, et al. J Clin Oncol. 2004 Apr 15;22(8):1430-8. doi: 10.1200/JCO.2004.10.112. J Clin Oncol. 2004. PMID: 15084616 Clinical Trial.
The treatment of advanced colorectal cancer: where are we now and where do we go?
Van Cutsem E, Verslype C, Demedts I. Van Cutsem E, et al. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):319-30. doi: 10.1053/bega.2002.0288. Best Pract Res Clin Gastroenterol. 2002. PMID: 11969241 Review.
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Verset G, et al. Br J Cancer. 2007 Sep 3;97(5):582-8. doi: 10.1038/sj.bjc.6603901. Epub 2007 Aug 7. Br J Cancer. 2007. PMID: 17687341 Free PMC article. Clinical Trial.
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, Deleporte A, Vergauwe P, Van Maanen A, Sempoux C, Van Cutsem E, Van Laethem JL; Belgian Group of Digestive Oncology. Borbath I, et al. Ann Oncol. 2013 Nov;24(11):2824-9. doi: 10.1093/annonc/mdt337. Epub 2013 Aug 23. Ann Oncol. 2013. PMID: 23975665 Clinical Trial.
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP. Van Cutsem E, et al. Ann Oncol. 2008 Feb;19(2):332-9. doi: 10.1093/annonc/mdm452. Epub 2007 Nov 6. Ann Oncol. 2008. PMID: 17986625 Clinical Trial.
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Van Laethem JL, Van Maele P, Verslype C, Polus M, Demols A, Houbiers G, Caenepeel P, Leleux A, Vermaut RR, Van Cutsem E, Peeters M. Van Laethem JL, et al. Oncology. 2004;67(5-6):338-43. doi: 10.1159/000082916. Oncology. 2004. PMID: 15713988 Clinical Trial.
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM. Hurwitz H, et al. Invest New Drugs. 2018 Aug;36(4):683-695. doi: 10.1007/s10637-018-0580-2. Epub 2018 Mar 6. Invest New Drugs. 2018. PMID: 29508247 Free PMC article. Clinical Trial.
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the ra …
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgro …
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D, Tejpar S, Spano JP, Verslype C, Bloch J, Vandecaveye V, Assadourian S, Soussan-Lazard K, Cartot-Coton S, Van Cutsem E. Khayat D, et al. Eur J Cancer. 2013 Mar;49(4):790-7. doi: 10.1016/j.ejca.2012.10.012. Epub 2013 Jan 10. Eur J Cancer. 2013. PMID: 23312881 Clinical Trial.
226 results
Jump to page
Feedback